Browse News

Found 605 articles

• TeselaGen and NinthBio Partner to Empower Users with Advanced DNA Variant Library Construction; Announcing Homology Path Design Algorithm Integration to Speed BioTech Development

  5/23/2023

  TeselaGen Biotechnology Inc., pioneer in AI-enabled Operating Systems for Biotechnology R&D and Manufacturing announces a strategic partnership with NinthBio LLC, the visionary Smart DNA Assembly Technology company.

• Kezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update

  5/11/2023

  Kezar Life Sciences, Inc. reported financial results for the first quarter ended March 31, 2023 and provided a business update.

• TeselaGen Support Helps Early-Stage BioTech Startups Scale Faster and More Efficiently with Its Starter Edition

  3/21/2023

  TeselaGen Biotechnology Inc. announces the launch of its Starter Edition, a version of TeselaGen's software supporting innovative early-stage biotech companies that are ready to scale.

• TransMed7, LLC Announces First Clinical Use of VacuPac®, a New Self-Contained, Vacuum-Assist Attachment for all of its Vacuum-Assisted, Single Insertion - Multiple Collection (SIMC®) Platforms of Biopsy Devices

  3/21/2023

  TransMed7, LLC announced the first clinical use of VacuPac®, a new self-contained external vacuum-assist attachment with a SpeedBird Universal and a Concorde US from the SpeedBird and Concorde families of vacuum-assisted, Single Insertion – Multiple Collection breast biopsy devices.

• Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

  3/14/2023

  Kezar Life Sciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2022 and provided a business update.

• Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023

  3/13/2023

  Kezar Life Sciences, Inc. today announced that the Company will pull forward its virtual Research and Development Day to Wednesday, March 15, 2023 at 4:30 pm ET/1:30 pm PT.

• ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones

  3/9/2023

  ALX Oncology Holdings Inc. reported financial results for the fourth quarter and year ended December 31, 2022 and provided clinical development and operational highlights.

• Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023

  3/6/2023

  Kezar Life Sciences, Inc. today announced that it will host a virtual Research and Development (R&D) Day on Wednesday, March 22, 2023 at 4:30 pm ET/1:30 pm PT.

• Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines

  3/1/2023

  Centessa Pharmaceuticals plc today announced the appointment of Patrick Yue, MD, to Centessa’s management team as Senior Vice President of Clinical Development, Innovative Medicines.

• Toragen, Inc. Announces Appointment of Chief Scientific Officer

  2/8/2023

  Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”), announced today that it has promoted Rick Lumpkin, PhD to the role of Chief Scientific Officer.

• TransMed7, LLC Announces First Clinical Cases of Concorde Soft Tissue Biopsy Devices for Commercial Launch

  2/6/2023

  TransMed7, LLC announced today that the “First in Human” series of clinical cases using commercial production Concorde US devices.

• ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023

  1/5/2023

  ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, provided a corporate update and highlighted key milestones anticipated in 2023.

• ALX Oncology Appoints Scott Garland to its Board of Directors

  11/29/2022

  ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced the appointment of Scott Garland to its Board of Directors effective November 29, 2022.

• ACELYRIN, INC. Adds Two Veteran C-suite Leaders

  11/10/2022

  ACELYRIN, INC. announced two executive appointments that will strengthen leadership of key corporate functions as the company enters its next stage of growth: Mardi C. Dier joins as Chief Financial Officer and Chief Business Officer while Mina Kim joins as Chief Legal and Administrative Officer.

• Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

  11/10/2022

  Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2022 and provided a business update.

• Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis

  10/3/2022

  Kezar Life Sciences, Inc. announced that it has received clearance of its Investigational New Drug application from the U.S. Food and Drug Administration for zetomipzomib, its first-in-class, selective immunoproteasome inhibitor, for the treatment of autoimmune hepatitis.

• Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

  9/26/2022

  Phathom Pharmaceuticals, Inc. today announced the appointment of James “Jamie” Topper, M.D., Ph.D., to its Board of Directors.

• TransMed7, LLC Announces First Clinical Use of Heron Soft Tissue Biopsy Devices for Commercial Launch

  8/16/2022

  TransMed7, LLC announced today that the “First in Human” clinical case of the commercial production version of a Heron™ XPS device (a member of the new Heron™ family of vacuum-assisted, Single Insertion / Multiple Collection (SIMC®) Soft Tissue Biopsy devices) was successfully performed by Dr. Edgar Staren.

• Toragen, Inc. Announces the Appointment of Board of Directors and Senior Staff

  8/15/2022

  Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus, announced the appointment of Mr. Paul Engler, of Amarillo, Texas, to the Board of Directors of the Company.

• TransMed7, LLC Announces First Clinical Use of SpeedBird™ Breast Biopsy Devices for Commercial Launch

  8/9/2022

  TransMed7, LLC announced today that the first clinical cases of the final commercial production version of the Sparrow device (a member of the new SpeedBird™ family of vacuum-assisted, Single Insertion / Multiple Collection (SIMC®) Breast Biopsy devices) were successfully performed by Dr. Edgar Staren, a distinguished surgeon and former President of the American Society of Breast Surgeons (ASBrS).